Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 297

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 297
---
 pill when patients are experiencing nausea as a result of the migraine headache. According to a study that was reported in 2001, Rizatriptan has a higher bioavailability and a more rapid onset of action which may be responsible for better results in resolving migraines as well as better results in patients reporting that they are “pain free” after 2 hours. Both Sumatriptan and Rizatriptan are competitors for the same indication, though neither are widely marketed because they are generic drugs. Ondansetron is an anti-emetic that is available in oral and intravenous form. An Ondansetron sublingual spray formulation (the “Ondansetron Spray Formulation”) may potentially have a faster onset of action than an oral form and may be easier to tolerate than swallowing a pill when patients are experiencing nausea. Under the terms of the Benuvia License Agreement, Benuvia will be responsible for the manufacturing and supply of the Spray Formulations, but Channel will have exclusive, worldwide rights to develop, commercialize and distribute the Spray Formulations. Channel currently does not have strategy and development plans for the Spray Formulations licensed from Benuvia. Channel’s Strategy Channel is a clinical-stage pharmaceutical company focused on non-opioid pain blockers in the NaV space. Its development programs are initially designed to address the underlying condition and mitigate the pain associated with neuropathic pain and eye pain. The key elements of its strategy to achieve its mission are:

| • | Develop CT2000 for the treatment of eye pain.According to a presentation at the Association for Research in Vision and Ophthalmology, with the abstract published in the publication, Investigative Ophthalmology and Visual Science in June 2020, NaV1.7 receptor is present on the cornea and as such, is a viable biological target for treating eye pain. Channel has developed a number of topical ophthalmic formulation |

165

TABLE OF CONTENTS

of CT2000 that are being evaluated for ophthalmic efficacy and toxicology in two in vivo models, which will be followed by a POC trial in patients. Channel expects the human POC trials for this ophthalmic formulation of CT2000 to start in the second quarter 2025.

| • | Develop CT3000 for the treatment of post-surgical pain.Based on its pre-clinical profile, and the target validation, if approved by the FDA, Channel believes that CT3000 has the potential to become a drug for treatment